As you know, NeoStem has undergone positive transformations this past year. The acquisition of Progenitor Cell Therapy (PCT) and Amorcyte furthers our progress in clinical development significantly. We have updated our website to reflect this change with a wealth of information about our own cell therapeutics. We continue to seek better ways to convey information about the value of NeoStem and our family of companies.
Our site’s “Clinical Development” section, found on the top navigation bar, includes information on our intellectual property portfolio and each of our pipeline product areas: Amorcyte, Athelos, VSELTM Technology and our wound technology. Please read more about NeoStem’s overarching clinical philosophy here as well. The clinical development section includes extensive information on Amorcyte and our most clinically advanced product candidate, AMR-001, which has recently begun patient enrollment for a Phase II trial for the treatment of acute myocardial infarction.
We are excited about updates to our site’s investor section as well. NeoStem has an active conference schedule for 2012 and we list upcoming events where our leadership team will be speaking under the “IR Events” tab. (Conferences attended by PCT are listed at the PCT website.) Our investor portal includes a concise, downloadable corporate profile as well as our updated investor presentation. We have also expanded information on how the acquisition of PCT enables our in-house clinical development, while bringing in revenues from client services.
I look forward to keeping you updated on company news and new website content as it becomes available.